Video

Andrew J. Cutler, MD: Neuroimaging for ADHD

Author(s):

Researchers have been unable to leverage new technology for ADHD screening.

Screening in attention deficit/ hyperactivity disorder (ADHD) remains a challenge in the field.

While technology has improved in other fields, researchers remain unable to develop a reliable and accurate method using neuroimaging or biomarkers to detect the disorder in patients.

Because of the complexities of the brain in compared to the heart, for example, developing these techniques may prove to be allusive.

In an interview with HCPLive®, Andrew J. Cutler, MD, Clinical Professor of Psychiatry at SUNY Upstate Medical University, explained the disappointment in the inability to leverage some of the emerging technologies being utilized in other spaces to detect ADHD early in patients.

Because of this it remains unknown or doubtful whether or not diagnostic practices in ADHD will change much in the next few years.

However, Cutler said currently screening techniques, which mainly involve self-assessment and interviews with teachers and family members, are effective.

In fact, it is common to detect the disorder in 5 or 6 year old children, and possible to diagnose a child as young as 2 or 3 with ADHD.

Cutler presented multiple times during the annual Neuroscience Education Institute Max! Virtual meeting on ADHD and other psychiatric disorders.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.